Terms: = Lymphoma AND TCF7L2, ENSG00000148737, 6934, TCF-4 AND Treatment
5 results:
1. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
Mizugaki H; Hamada A; Shibata T; Hosoda F; Nakamura H; Okuma Y; Shukuya T; Umemura S; Horiike A; Fukui T; Kogure Y; Daga H; Urata Y; Yamada K; Saeki S; Fujisaka Y; Nakamura Y; Sato M; Yoshida T; Hotta T; Oizumi S; Fujiwara Y; Ohe Y; Fujiwara Y
Lung Cancer; 2019 Feb; 128():20-25. PubMed ID: 30642448
[TBL] [Abstract] [Full Text] [Related]
2. tcf7l2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Zhao Q; Zhao S; Li J; Zhang H; Qian C; Wang H; Liu J; Zhao Y
Biomed Pharmacother; 2019 Jan; 109():1640-1649. PubMed ID: 30551418
[TBL] [Abstract] [Full Text] [Related]
3. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract] [Full Text] [Related]
4. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
[TBL] [Abstract] [Full Text] [Related]
5. JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.
Nath N; Chattopadhyay M; Pospishil L; Cieciura LZ; Goswami S; Kodela R; Saavedra JE; Keefer LK; Kashfi K
Biochem Pharmacol; 2010 Dec; 80(11):1641-9. PubMed ID: 20797387
[TBL] [Abstract] [Full Text] [Related]